Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line
Myxofibrosarcoma (MFS) belongs to the group of sarcoma tumors, which represent only 1% of the totality of adult tumors worldwide. Thus, given the rare nature of this cancer, this makes the availability of MFS cell lines difficult. In an attempt to partially fill this gap, we immortalized a primary c...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/7/11/186 |
| _version_ | 1797710923190763520 |
|---|---|
| author | Giacomo Miserocchi Alessandro De Vita Laura Mercatali Federica Recine Chiara Liverani Chiara Spadazzi Federica Pieri Nada Riva Alberto Bongiovanni Roberto Casadei Valentina Fausti Toni Ibrahim |
| author_facet | Giacomo Miserocchi Alessandro De Vita Laura Mercatali Federica Recine Chiara Liverani Chiara Spadazzi Federica Pieri Nada Riva Alberto Bongiovanni Roberto Casadei Valentina Fausti Toni Ibrahim |
| author_sort | Giacomo Miserocchi |
| collection | DOAJ |
| description | Myxofibrosarcoma (MFS) belongs to the group of sarcoma tumors, which represent only 1% of the totality of adult tumors worldwide. Thus, given the rare nature of this cancer, this makes the availability of MFS cell lines difficult. In an attempt to partially fill this gap, we immortalized a primary culture of MFS (IM-MFS-1) and compared the cell morphology with patient’s tumor tissue. IM-MFS-1 was genetically characterized through a Comparative Genomic Hybridization (CGH) array and the mesenchymal phenotype was evaluated using Polymerase chain reaction (PCR) and immunofluorescence staining. Drug sensitivity for MFS therapies was monitored over time in cultures. We confirmed the conservation of the patient’s tumor cell morphology and of the mesenchymal phenotype. Conversely, the synthesis and expression of CD109, a TGFβ co-receptor used to facilitate the diagnosis of high-grade MFS diagnosis, was maintained constant until high cancer cell line passages. The CGH array revealed a complex karyotype with cytogenetic alterations that include chromosome regions associated with genes involved in tumor processes. Cytotoxicity assays show drug sensitivity constantly increased during the culture passages until a plateau was reached. In conclusion, we established and characterized a new MFS cell line that can be used for future preclinical and molecular studies on soft tissue sarcomas. |
| first_indexed | 2024-03-12T06:59:20Z |
| format | Article |
| id | doaj.art-b527fbfb44b9481b9dc0f83cf78a1a6f |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-12T06:59:20Z |
| publishDate | 2018-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-b527fbfb44b9481b9dc0f83cf78a1a6f2023-09-02T23:49:41ZengMDPI AGCells2073-44092018-10-0171118610.3390/cells7110186cells7110186Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell LineGiacomo Miserocchi0Alessandro De Vita1Laura Mercatali2Federica Recine3Chiara Liverani4Chiara Spadazzi5Federica Pieri6Nada Riva7Alberto Bongiovanni8Roberto Casadei9Valentina Fausti10Toni Ibrahim11Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, ItalyOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, ItalyOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, ItalyOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, ItalyOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, ItalyOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, ItalyPathology Unit, Morgagni-Pierantoni Hospital, Via Carlo Forlanini 34, 47100 Forlì, ItalyOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, ItalyOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, ItalyOrthopedic Unit, AUSL della Romagna -Forlì, Via Carlo Forlanini 34, 47100 Forlì, ItalyOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, ItalyOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, ItalyMyxofibrosarcoma (MFS) belongs to the group of sarcoma tumors, which represent only 1% of the totality of adult tumors worldwide. Thus, given the rare nature of this cancer, this makes the availability of MFS cell lines difficult. In an attempt to partially fill this gap, we immortalized a primary culture of MFS (IM-MFS-1) and compared the cell morphology with patient’s tumor tissue. IM-MFS-1 was genetically characterized through a Comparative Genomic Hybridization (CGH) array and the mesenchymal phenotype was evaluated using Polymerase chain reaction (PCR) and immunofluorescence staining. Drug sensitivity for MFS therapies was monitored over time in cultures. We confirmed the conservation of the patient’s tumor cell morphology and of the mesenchymal phenotype. Conversely, the synthesis and expression of CD109, a TGFβ co-receptor used to facilitate the diagnosis of high-grade MFS diagnosis, was maintained constant until high cancer cell line passages. The CGH array revealed a complex karyotype with cytogenetic alterations that include chromosome regions associated with genes involved in tumor processes. Cytotoxicity assays show drug sensitivity constantly increased during the culture passages until a plateau was reached. In conclusion, we established and characterized a new MFS cell line that can be used for future preclinical and molecular studies on soft tissue sarcomas.https://www.mdpi.com/2073-4409/7/11/186myxofibrosarcomaprimary cultureCD109cell line establishment |
| spellingShingle | Giacomo Miserocchi Alessandro De Vita Laura Mercatali Federica Recine Chiara Liverani Chiara Spadazzi Federica Pieri Nada Riva Alberto Bongiovanni Roberto Casadei Valentina Fausti Toni Ibrahim Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line Cells myxofibrosarcoma primary culture CD109 cell line establishment |
| title | Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line |
| title_full | Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line |
| title_fullStr | Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line |
| title_full_unstemmed | Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line |
| title_short | Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line |
| title_sort | characterization and drug sensitivity of a new high grade myxofibrosarcoma cell line |
| topic | myxofibrosarcoma primary culture CD109 cell line establishment |
| url | https://www.mdpi.com/2073-4409/7/11/186 |
| work_keys_str_mv | AT giacomomiserocchi characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline AT alessandrodevita characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline AT lauramercatali characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline AT federicarecine characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline AT chiaraliverani characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline AT chiaraspadazzi characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline AT federicapieri characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline AT nadariva characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline AT albertobongiovanni characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline AT robertocasadei characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline AT valentinafausti characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline AT toniibrahim characterizationanddrugsensitivityofanewhighgrademyxofibrosarcomacellline |